In particular, the combination of standard chemotherapy and hnRNPA2B1-BIRC5 inhibitors will more effectively eliminate tumor stem cells and other tumor cells, thereby reducing the incidence of drug resistance. The gene discussed is HNRNPA2B1; the disease is neoplasm.